Abstract Library

#4608 A complex and rare association of neuroendocrine and endocrine neoplasms: A case report

Introduction: Neuroendocrine tumours (NETs) are sporadic or genetically inherited heterogenous neoplasms affecting multiple sites.

Conference:

Presenting Author: Cerroni L

Authors: Cerroni L, Filice A, Feola T, Sesti F, Vincenzi L,

Keywords: cushing disease, atypical carcinoid, ileal net, genetics,

#3842 Long response to 177-Lu DOTATATE of a long malignant metastatic pheochromocytoma survivor

Introduction: A 64-year-old man was admitted on November 2010 with a CT-scan showing a 9cm right adrenal mass and high 24-hour urine metanephrins and cathecolamins. The mass was resected in December 2010 confirming a pT3N1 pheochromocytoma (PHEO). In May 2013 he presented a local recurrence that was resected proving metastatic lymphatic tissue. On May 2014 biochemical progression preceded a CT scan showing retroperitoneal lymphadenophaties with MIBG uptake. He was then treated with 131I-MIBG (two cycles) until May 2015, having biochemical and radiological response. After lymphatic tumor progression in January 2018, he received two more cycles of 131I-MIBG therapy (cumulative dose 800mCi) with proven refractory disease. He continued follow-up until two new abdominal masses appeared in October 2020. A high uptake in the 99Tc octreotide scintigraphy showed somatostatin receptors expression. The patient refused to participate in a clinical trial, so he was treated off-label with 177Lu-DOTATATE (800mCi) four doses from February to July 2021 achieving a near-complete response.

Conference:

Presenting Author: Martin Fernandez de Soignie A

Authors: Martin Fernandez de Soignie A, Martinez Moreno E, Antón-Pascual B, Pantin Gonzalez C, Sanchez Baños N,

Keywords: pheochromocytoma, 177-Lutetium,

#3423 MIBG scintigraphy in metastatic neuroblastoma: A retrospective study of 25 cases

Introduction: Meta-iodobenzylguanidine (MIBG) scintigraphy is the first-line functional imaging agent used in neuroblastoma imaging, identifying both the primary tumor and sites of metastatic disease.

Conference:

Presenting Author:

Authors: Ghomari C, Nasri A, Tahraoui Z, Merad S, Medjahedi A,

Keywords: I-MIBG, neuroblastoma, metastasis,

#3421 131I-MIBG scintigraphy in the diagnosis of pheochromocytoma: Retrospective study of 50 cases

Introduction: Pheochromocytoma is a rare tumor of the adrenal medulla. Its exploration with Metaiodobenzylguanidine (MIBG) scintigraphy is one of the current standard diagnostic procedures.

Conference:

Presenting Author:

Authors: Ghomari C, Tahraoui Z, Merad S, Medjahedi A,

Keywords: 131I-MIBG, pheochromocytoma, specificity,

#941 Comparison of Radiolableled Somatostatin Analogues and (131) I-MIBG Treatment for the Management of Patients with Metastatic/Progressive Phaeochromocytomas and Paragangliomas

Introduction: Radionuclide therapy has been used to treat patients with progressive/metastatic paragangliomas (PGGs) and pheochromocytomas (PCCs). To date, there is no study comparing (131)I-MIBG and peptide receptor radionuclide treatment (PRRT) in those patients.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Nastos K, Toumpanakis C, Cheung V, Navalkissoor S, Quigley A,

Keywords: paraganglioma, pheochromocytoma, (131)I-MIBG, PRRT,